Since 2010, mAbs has documented the biopharmaceutical industry's progress in 
transitioning antibody therapeutics to first Phase 3 clinical studies and 
regulatory review, and its success at gaining first marketing approvals for 
antibody-based products. This installment of the "Antibodies to watch" series 
outlines events anticipated to occur between December 2013 and the end of 2014, 
including first regulatory actions on marketing applications for vedolizumab, 
siltuximab, and ramucirumab, as well as the Fc fusion proteins Factor IX-Fc and 
Factor VIII-Fc; and the submission of first marketing applications for up to 
five therapeutics (secukinumab, ch14.18, onartuzumab, necitumumab, gevokizumab). 
Antibody therapeutics in Phase 3 studies are described, with an emphasis on 
those with study completion dates in 2014, including antibodies targeting 
interleukin-17a or the interleukin-17a receptor (secukinumab, ixekizumab, 
brodalumab), proprotein convertase subtilisin/kexin type 9 (alirocumab, 
evolocumab, bococizumab), and programmed death 1 receptor (lambrolizumab, 
nivolumab). Five antibodies with US Food and Drug Administration's Breakthrough 
Therapy designation (obinutuzumab, ofatumumab, lambrolizumab, bimagrumab, 
daratumumab) are also discussed.